Luis Paz Ares, MD
Hospital 12 de Octubre · Spanish Lung Cancer Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Luis Paz Ares, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03496766 · Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionSSpanish Lung Cancer Group · terminated · Non Small Cell Lung Cancer · study chair
- Ph3NCT00446225 · Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFRSpanish Lung Cancer Group · completed · Non-Small Cell Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.